Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Fuzuloparib by Jiangsu Hengrui Medicine for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Fuzuloparib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According...
Fuzuloparib by Jiangsu Hengrui Medicine for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Fuzuloparib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC)....
Fuzuloparib by Jiangsu Hengrui Medicine for Pancreatic Cancer: Likelihood of Approval
Fuzuloparib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Pancreatic Cancer. According to GlobalData,...